PRODUCT INFORMATION



Famotidine-¹³C-d₂

Item No. 31493

CAS Registry No.:	2744683-81-4	
Formal Name:	3-[[[2-[(aminoiminomethyl)amino]-4-	
	thiazolyl]methyl]thio]-N-(aminosulfonyl)- propanimidamide1- ¹³ C-2,3,3-d ₃	NH O O
MF:	C ₇ [¹³ C]H ₁₂ D ₃ N ₇ O ₂ S ₃	
FW:	341.5	
Chemical Purity:	≥95% (Famotidine)	
Deuterium		H ₂ N—(S
Incorporation:	≥99% deuterated forms (d₁-d₃); ≤1% d₀	
Supplied as:	A solid	
Storage:	-20°C	
Stability:	≥4 years	
Information represents the product encodifications. Databasecific and tical results are previded on each contificate of analysis		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Famotidine-¹³C-d₂ is intended for use as an internal standard for the quantification of famotidine (Item No. 23828) by GC- or LČ-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Famotidine-¹³C-d₃ is supplied as a solid. A stock solution may be made by dissolving the famotidine-¹³C-d₃ in the solvent of choice, which should be purged with an inert gas. Famotidine- 13 C-d₂ is soluble in methanol, DMSO, and dimethyl formamide.

Description

Famotidine is a histamine H_2 receptor antagonist with a K_i value of 12 nM in fractionated guinea pig cerebral cortex membranes.¹ It is selective for H₂ over H₁ and muscarinic receptors (K_is = 4 and 28 μ M, respectively, in bovine cerebral cortex).² Famotidine inhibits histamine-induced acid secretion in isolated canine parietal cells (IC₅₀ = 0.6 µM).³ It also suppresses histamine-induced gastric acid secretion in dogs when administered orally and in anesthetized rats when administered intraduodenally ($ID_{50}s = 10$ and 400 μ g/kg, respectively).³ Formulations containing famotidine have been used in the treatment of ulcers, gastroesophageal reflux disease (GERD), and heartburn, as well as to decrease the risk of gastrointestinal toxicity associated with non-steroidal anti-inflammatory drugs (NSAIDs).

References

- 1. Gajtkowski, G.A., Norris, D.B., Rising, T.J., et al. Specific binding of ³H-tiotidine to histamine H₂ receptors in guinea pig cerebral cortex. Nature 304(5921), 65-67 (1983).
- 2. Kubo, N., Shirakawa, S., Kuno, T., et al. Antimuscarinic effects of antihistamines: Quantitative evaluation by receptor-binding assay. Jpn. J. Pharmacol. 43(3), 277-282 (1987).
- 3. Nagaya, H., Inatomi, N., and Satoh, H. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H_2 -receptor antagonist famotidine in rats and dogs. Jpn. J. Pharmacol. 55(4), 425-436 (1991).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 12/22/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM